Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patients.

doi:10.1128/AAC.49.5.1720-1726.2005

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patients.

Antimicrobial agents and chemotherapy - 1 May 2005

Marcelin Anne-Geneviève, Cohen-Codar Isabelle, King Martin S, Colson Philippe, Guillevic Emmanuel, Descamps Diane, Lamotte Claire, Schneider Véronique, Ritter Jacques, Segondy Michel, Peigue-Lafeuille Hélène, Morand-Joubert Laurence, Schmuck Anne, Ruffault Annick, Palmer Pierre, Chaix Marie-Laure, Mackiewicz Vincent, Brodard Véronique, Izopet Jacques, Cottalorda Jacqueline, Kohli Evelyne, Chauvin Jean-Pierre, Kempf Dale J, Peytavin Gilles, Calvez Vincent

Abstract excerpt

The genotypic inhibitory quotient (GIQ) has been proposed as a way to integrate drug exposure and genotypic resistance to protease inhibitors and can be useful to enhance the predictivity of virologic response for boosted protease inhibitors. The aim of this study was to evaluate the predictivity...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Combinations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Monitoring

Share to HIV Protease Inhibitors

Share to Linear Models

Share to Lopinavir

Share to Predictive Value of Tests

Share to Pyrimidinones

Share to Ritonavir

Source

Open in PubMed Open full text

Identifiers

PMID: 15855487
DOI: 10.1128/AAC.49.5.1720-1726.2005
PMCID: PMC1087618

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-15855487-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patients.PMID 15855487Read ↗

Ability of different lopinavir genotypic inhibitory quotients to predict 48-week virological response in highly treatment-experienced HIV-infected patients receiving lopinavir/ritonavir.Semantic proximity Read ↗

Prediction of early and confirmed virological response by genotypic inhibitory quotients for lopinavir in patients naïve for lopinavir with limited exposure to previous protease inhibitors.Semantic proximity Read ↗

The use of drug resistance algorithms and genotypic inhibitory quotient in prediction of lopinavir-ritonavir treatment response in human immunodeficiency virus type 1 protease inhibitor-experienced patients.Semantic proximity Read ↗

Prediction of virological response to lopinavir/ritonavir using the genotypic inhibitory quotient.Semantic proximity Read ↗

Virological, intracellular and plasma pharmacological parameters predicting response to lopinavir/ritonavir (KALEPHAR study).Semantic proximity Read ↗

The genotypic inhibitory quotient and the (cumulative) number of mutations predict the response to lopinavir therapy.Semantic proximity Read ↗

The NIQ of lopinavir is predictive of a 48-week virological response in highly treatment-experienced HIV-1-infected subjects treated with a lopinavir/ritonavir-containing regimen.Semantic proximity Read ↗

Predictive value of drug levels, HIV genotyping, and the genotypic inhibitory quotient (GIQ) on response to saquinavir/ritonavir in antiretroviral-experienced HIV-infected patients.Semantic proximity Read ↗

Predictive values of the human immunodeficiency virus phenotype and genotype and of amprenavir and lopinavir inhibitory quotients in heavily pretreated patients on a ritonavir-boosted dual-protease-inhibitor regimen.Semantic proximity Read ↗

Predictive value of pharmacokinetics-adjusted phenotypic susceptibility on response to ritonavir-enhanced protease inhibitors (PIs) in human immunodeficiency virus-infected subjects failing prior PI therapy.Semantic proximity Read ↗

Darunavir inhibitory quotient predicts the 48-week virological response to darunavir-based salvage therapy in human immunodeficiency virus-infected protease inhibitor-experienced patients.Semantic proximity Read ↗

The normalized inhibitory quotient of boosted protease inhibitors is predictive of viral load response in treatment-experienced HIV-1-infected individuals.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.